news
Pfizer and Allergan considering a merger
29 October 2015 | By Victoria White
Allergan has said that it is in preliminary “friendly discussions” with Pfizer regarding a potential business combination transaction...
List view / Grid view
Allergan Inc.
news
Allergan acquires rights to Constella in more than 40 countries
27 October 2015 | By Victoria White
The license agreement includes the development and commercialisation of Constella for the treatment of irritable bowel syndrome with constipation and other gastrointestinal conditions...
news
Botox effective long-term treatment for overactive bladder in women
16 October 2015 | By Victoria White
Results from an extension study show that long-term onabotulinumtoxinA (Botox) treatment consistently decreased urinary incontinence in female patients...
news
Allergan completes $2.1 billion acquisition of Kythera
1 October 2015 | By Victoria White
The acquisition of Kythera adds Kybella, an injection for improvement in the appearance of moderate to severe submental fullness, to Allergan’s portfolio...
news
Biosimilar ABP 215 meets endpoints in Phase 3 study in NSCLC
24 September 2015 | By Victoria White
ABP 215 is being developed as a biosimilar to bevacizumab, a recombinant immunoglobulin G1 (IgG1) monoclonal antibody (mAb)...
news
FDA approves Vraylar for schizophrenia and bipolar disorder
21 September 2015 | By Victoria White
The FDA approval is based on the results of three 3-week controlled trials in adults with bipolar I disorder and three 6-week placebo-controlled trials in adults with schizophrenia...
news
FDA approves Abbreviated NDAs for Mucinex equivalent products
11 September 2015 | By Victoria White
Allergan has said that its partner, Perrigo, will begin shipments of the products to its retail and wholesale customers in the US in time for the 2016 cough and cold season...
news
Allergan to acquire glaucoma treatment company AqueSys
4 September 2015 | By Victoria White
Allergan is to acquire AqueSys for a $300 million upfront payment and milestone payments related to AqueSys' lead development programmes, including XEN45...
news
FDA approves label update for Teflaro
2 September 2015 | By Victoria White
Teflaro is now approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia...
news
Positive Phase III results demonstrate efficacy of Avycaz
2 September 2015 | By Victoria White
Positive results from RECAPTURE 1 and 2, Phase III studies evaluating the antibiotic Avycaz as a treatment for patients with cUTI, have been announced...
news
Allergan acquires Naurex; strengthens mental health pipeline
2 September 2015 | By Victoria White
Allergan has completed the acquisition of Naurex, a biopharmaceutical company developing therapies for challenging disorders of the central nervous system...
news
Allergan confirms generic Tyvaso patent challenge
30 July 2015 | By Victoria White
Allergan has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market a generic version of United Therapeutics' Tyvaso...
news
Teva withdraws proposal to acquire Mylan
28 July 2015 | By Victoria White
Following yesterday’s news that Teva is to acquire Allergan’s global generics business, Teva has withdrawn its cash and stock proposal to acquire Mylan...
news
Allergan to acquire Naurex; divests generics business to Teva
27 July 2015 | By Victoria White
Allergan followed an announcement it made yesterday about its acquisition of Naurex with news today that it is to divest its generics business to Teva...
news
Allergan receives Paragraph IV notification on Restasis
16 July 2015 | By Victoria White
Akorn Pharmaceuticals seeks approval to market a generic version of Allergan's Restasis from the US Food and Drug Administration FDA...
